跳转至内容
Merck
CN
  • Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis.

Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis.

Analytical chemistry (2014-08-02)
John G Swales, James W Tucker, Nicole Strittmatter, Anna Nilsson, Diego Cobice, Malcolm R Clench, C Logan Mackay, Per E Andren, Zoltán Takáts, Peter J H Webborn, Richard J A Goodwin
摘要

Cassette dosing of compounds for preclinical drug plasma pharmacokinetic analysis has been shown to be a powerful strategy within the pharmaceutical industry for increasing throughput while decreasing the number of animals used. Presented here for the first time is data on the application of a cassette dosing strategy for label-free tissue distribution studies. The aim of the study was to image the spatial distribution of eight nonproprietary drugs (haloperidol, bufuralol, midazolam, clozapine, terfenadine, erlotinib, olanzapine, and moxifloxacin) in multiple tissues after oral and intravenous cassette dosing (four compounds per dose route). An array of mass spectrometry imaging technologies, including matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI MSI), liquid extraction surface analysis tandem mass spectrometry (LESA-MS/MS), and desorption electrospray ionization mass spectrometry (DESI-MS) was used. Tissue analysis following intravenous and oral administration of discretely and cassette-dosed compounds demonstrated similar relative abundances across a range of tissues indicating that a cassette dosing approach was applicable. MALDI MSI was unsuccessful in detecting all of the target compounds; therefore, DESI MSI, a complementary mass spectrometry imaging technique, was used to detect additional target compounds. In addition, by adapting technology used for tissue profiling (LESA-MS/MS) low spatial resolution mass spectrometry imaging (∼1 mm) was possible for all targets across all tissues. This study exemplifies the power of multiplatform MSI analysis within a pharmaceutical research and development (R&D) environment. Furthermore, we have illustrated that the cassette dosing approach can be readily applied to provide combined, label-free pharmacokinetic and drug distribution data at an early stage of the drug discovery/development process while minimizing animal usage.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
2-甲基丁烷, ReagentPlus®, ≥99%
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Sigma-Aldrich
乙腈, anhydrous, 99.8%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙腈, ≥99.9% (GC)
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
2-甲基丁烷, ReagentPlus®, ≥99%
Sigma-Aldrich
乙腈, suitable for HPLC-GC, ≥99.8% (GC)
Sigma-Aldrich
2-甲基丁烷, suitable for HPLC, ≥99.5%
Sigma-Aldrich
2,5-二羟基苯甲酸, 98%
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Supelco
甲醇, analytical standard
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
2,5-二羟基苯甲酸, suitable for matrix substance for MALDI-MS, >99.0% (HPLC)
Sigma-Aldrich
乙腈, biotech. grade, ≥99.93%
Sigma-Aldrich
乙腈, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
2-甲基丁烷, anhydrous, ≥99%
Sigma-Aldrich
甲酸, ≥95%, FCC, FG